Glucagon‑like peptide‑1 protects mouse podocytes against high glucose‑induced apoptosis, and suppresses reactive oxygen 
species production and proinflammatory cytokine secretion, through sirtuin 1 activation in vitro

Shi,Jian‑Xia; Huang,Qin

doi:10.3892/mmr.2018.9085

Glucagon‑like peptide‑1 protects mouse podocytes against high glucose‑induced apoptosis, and suppresses reactive oxygen species production and proinflammatory cytokine secretion, through sirtuin 1 activation in vitro

Authors:
- Jian‑Xia Shi
- Qin Huang
View Affiliations

Affiliations: Department of Endocrinology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, P.R. China
Published online on: May 29, 2018 https://doi.org/10.3892/mmr.2018.9085
Pages: 1789-1797

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucagon‑like peptide‑1 (GLP‑1) is a gut incretin hormone that is considered to be a promising target for the treatment of patients with type 2 diabetes. However, the mechanisms underlying the protective effects of GLP‑1 on diabetic nephropathy are yet to be fully elucidated. Sirtuin (SIRT)1 encodes a member of the SIRT family of proteins that serves an important role in mitochondrial function and is reported to be associated with the pathogenesis of chronic kidney disease. The present study treated mouse podocytes with various concentrations of D‑glucose to establish a high glucose (HG)‑induced model of renal injury. The results of a 2',7'‑dichlorodihydrofluorescein diacetate assay, Annexin V/propidium iodide staining and ELISA demonstrated that treatment of podocytes with HG significantly enhanced the production of reactive oxygen species (ROS), promoted cell apoptosis and increased the secretion of proinflammatory cytokines, respectively. The cytokines increased following HG treatment included tumor necrosis factor‑α, interleukin (IL)‑1β and IL‑6. Notably, treatment with GLP‑1 attenuated HG‑induced increases in ROS production and podocyte apoptosis, which may occur via downregulation of the expression of caspase‑3 and caspase‑9, and increased expression of nephrin, podocin and SIRT1, as determined by reverse transcription‑quantitative polymerase chain reaction and western blot analysis. Treatment with GLP‑1 led to protective effects in podocytes that were similar to those of resveratrol. Furthermore, SIRT1 knockdown using short hairpin RNA significantly enhanced the expression of caspase‑3 and caspase‑9 in mouse podocytes, compared with normal mouse podocytes. SIRT1 knockdown with or without GLP‑1 administration significantly decreased the expression of caspase‑3 and caspase‑9 in mouse podocytes, compared with SIRT1 knockdown mouse podocytes. In conclusion, the results of the present study indicated that GLP‑1 may be a promising target for the development of novel therapeutic strategies for HG‑induced nephropathy, and may function through the activation of SIRT1.

View Figures

View References

1	Marques C, Mega C, Goncalves A, Rodrigues-Santos P, Teixeira-Lemos E, Teixeira F, Fontes-Ribeiro C, Reis F and Fernandes R: Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators Inflamm. 2014:5387372014. View Article : Google Scholar : PubMed/NCBI
2	Panduru NM, Saraheimo M, Forsblom C, Thorn LM, Gordin D, Wadén J, Tolonen N, Bierhaus A, Humpert PM and Groop PH: FinnDiane Study Group: Urinary adiponectin is an independent predictor of progression to end-stage renal disease in patients with type 1 diabetes and diabetic nephropathy. Diabetes Care. 38:883–890. 2015. View Article : Google Scholar : PubMed/NCBI
3	Wu Y, Dong J, Yuan L, Liang C, Ren K, Zhang W, Fang F and Shen J: Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy. Cytokine. 44:85–91. 2008. View Article : Google Scholar : PubMed/NCBI
4	Jim B, Ghanta M, Qipo A, Fan Y, Chuang PY, Cohen HW, Abadi M, Thomas DB and He JC: Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: A cross sectional study. PLoS One. 7:e360412012. View Article : Google Scholar : PubMed/NCBI
5	Liu BC, Song X, Lu XY, Li DT, Eaton DC, Shen BZ, Li XQ and Ma HP: High glucose induces podocyte apoptosis by stimulating TRPC6 via elevation of reactive oxygen species. Biochim Biophys Acta. 1833:1434–1442. 2013. View Article : Google Scholar : PubMed/NCBI
6	Shah A, Xia L, Goldberg H, Lee KW, Quaggin SE and Fantus IG: Thioredoxin-interacting protein mediates high glucose-induced reactive oxygen species generation by mitochondria and the NADPH oxidase, Nox4, in mesangial cells. J Biol Chem. 288:6835–6848. 2013. View Article : Google Scholar : PubMed/NCBI
7	Brezniceanu ML, Liu F, Wei CC, Chénier I, Godin N, Zhang SL, Filep JG, Ingelfinger JR and Chan JS: Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes. 57:451–459. 2008. View Article : Google Scholar : PubMed/NCBI
8	Purwata TE: High TNF-alpha plasma levels and macrophages iNOS and TNF-alpha expression as risk factors for painful diabetic neuropathy. J Pain Res. 4:169–175. 2011. View Article : Google Scholar : PubMed/NCBI
9	Xu L, Shen P, Bi Y, Chen J, Xiao Z, Zhang X and Wang Z: Danshen injection ameliorates STZ-induced diabetic nephropathy in association with suppression of oxidative stress, pro-inflammatory factors and fibrosis. Int Immunopharmacol. 38:385–394. 2016. View Article : Google Scholar : PubMed/NCBI
10	Bălăşescu E, Cioplea M, Brinzea A, Nedelcu R, Zurac S and Ion DA: Immunohistochemical aspects of cell death in diabetic nephropathy. Rom J Intern Med. 54:54–62. 2016.PubMed/NCBI
11	Drucker DJ: The biology of incretin hormones. Cell Metab. 3:153–165. 2006. View Article : Google Scholar : PubMed/NCBI
12	Gupta A, Jelinek HF and Al-Aubaidy H: Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus. Diabetes Metab Syndr. 11:225–230. 2017. View Article : Google Scholar : PubMed/NCBI
13	Shen M, Sun D, Li W, Liu B, Wang S, Zhang Z and Cao F: The synergistic effect of valsartan and LAF237 ((S)-1-((3-hydroxy-1-adamantyl)ammo)acetyl-2-cyanopyrrolidine) on vascular oxidative stress and inflammation in type 2 diabetic mice. Exp Diabetes Res. 2012:1461942012. View Article : Google Scholar : PubMed/NCBI
14	Ishibashi Y, Nishino Y, Matsui T, Takeuchi M and Yamagishi S: Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism. 60:1271–1277. 2011. View Article : Google Scholar : PubMed/NCBI
15	Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, Zhang R, Su T, Ma X, Zeng C, et al: Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes. 62:1697–1708. 2013. View Article : Google Scholar : PubMed/NCBI
16	Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, et al: Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 54:965–978. 2011. View Article : Google Scholar : PubMed/NCBI
17	Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD and Chang YS: Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol. 18:1227–1238. 2007. View Article : Google Scholar : PubMed/NCBI
18	Kitada M, Kume S, Takeda-Watanabe A, Kanasaki K and Koya D: Sirtuins and renal diseases: Relationship with aging and diabetic nephropathy. Clinical sci (Lond). 124:153–164. 2013. View Article : Google Scholar
19	Chalkiadaki A and Guarente L: Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat Rev Endocrinol. 8:287–296. 2012. View Article : Google Scholar : PubMed/NCBI
20	He W, Wang Y, Zhang MZ, You L, Davis LS, Fan H, Yang HC, Fogo AB, Zent R, Harris RC, et al: Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest. 120:1056–1068. 2010. View Article : Google Scholar : PubMed/NCBI
21	Kume S, Uzu T, Horiike K, Chin-Kanasaki M, Isshiki K, Araki S, Sugimoto T, Haneda M, Kashiwagi A and Koya D: Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest. 120:1043–1055. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kume S, Kitada M, Kanasaki K, Maegawa H and Koya D: Anti-aging molecule, Sirt1: A novel therapeutic target for diabetic nephropathy. Arch Pharm Res. 36:230–236. 2013. View Article : Google Scholar : PubMed/NCBI
23	Shi JX, Wang QJ, Li H and Huang Q: Silencing of USP22 suppresses high glucose-induced apoptosis, ROS production and inflammation in podocytes. Mol Biosyst. 12:1445–1456. 2016. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Nishikawa T, Brownlee M and Araki E: Mitochondrial reactive oxygen species in the pathogenesis of early diabetic nephropathy. J Diabetes Investig. 6:137–139. 2015. View Article : Google Scholar : PubMed/NCBI
26	Yacoub R, Lee K and He JC: The Role of SIRT1 in diabetic kidney disease. Front Endocrinol (Lausanne). 5:1662014.PubMed/NCBI
27	Susztak K, Raff AC, Schiffer M and Bottinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 55:225–233. 2006. View Article : Google Scholar : PubMed/NCBI
28	Saleem MA, Ni L, Witherden I, Tryggvason K, Ruotsalainen V, Mundel P and Mathieson PW: Co-localization of nephrin, podocin, and the actin cytoskeleton: Evidence for a role in podocyte foot process formation. Am J Pathol. 161:1459–1466. 2002. View Article : Google Scholar : PubMed/NCBI
29	Bock F, Shahzad K, Wang H, Stoyanov S, Wolter J, Dong W, Pelicci PG, Kashif M, Ranjan S, Schmidt S, et al: Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci USA. 110:648–653. 2013. View Article : Google Scholar : PubMed/NCBI
30	Allen DA, Harwood S, Varagunam M, Raftery MJ and Yaqoob MM: High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases. FASEB J. 17:908–910. 2003. View Article : Google Scholar : PubMed/NCBI
31	Tews D, Lehr S, Hartwig S, Osmers A, Paslack W and Eckel J: Anti-apoptotic action of exendin-4 in INS-1 beta cells: comparative protein pattern analysis of isolated mitochondria. Horm Metab Res. 41:294–301. 2009. View Article : Google Scholar : PubMed/NCBI
32	Lim AK and Tesch GH: Inflammation in diabetic nephropathy. Mediators Inflamm. 2012:1461542012. View Article : Google Scholar : PubMed/NCBI
33	Guo C, Huang T, Chen A, Chen X, Wang L, Shen F and Gu X: Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages. Braz J Med Biol Res. 49:e58262016. View Article : Google Scholar : PubMed/NCBI
34	Kitada M, Kume S, Kanasaki K, Takeda-Watanabe A and Koya D: Sirtuins as possible drug targets in type 2 diabetes. Curr Drug Targets. 14:622–636. 2013. View Article : Google Scholar : PubMed/NCBI
35	Wang XL, Wu LY, Zhao L, Sun LN, Liu HY, Liu G and Guan GJ: SIRT1 activator ameliorates the renal tubular injury induced by hyperglycemia in vivo and in vitro via inhibiting apoptosis. Biomed Pharmacother. 83:41–50. 2016. View Article : Google Scholar : PubMed/NCBI